1
|
Doughan A, Salifu SP. Genes associated with diagnosis and prognosis of Burkitt lymphoma. IET Syst Biol 2022; 16:220-229. [PMID: 36354023 PMCID: PMC9675412 DOI: 10.1049/syb2.12054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 08/30/2022] [Accepted: 10/27/2022] [Indexed: 11/11/2022] Open
Abstract
Burkitt lymphoma (BL) is one of the most aggressive forms of non-Hodgkin's lymphomas that affect children and young adults. The expression of genes and other molecular markers during carcinogenesis can be the basis for diagnosis, prognosis and the design of new and effective drugs for the management of cancers. The aim of this study was to identify genes that can serve as prognostic and therapeutic targets for BL. We analysed RNA-seq data of BL transcriptome sequencing projects in Africa using standard RNA-seq analyses pipeline. We performed pathway enrichment analyses, protein-protein interaction networks, gene co-expression and survival analyses. Gene and pathway enrichment analyses showed that the differentially expressed genes are involved in tube development, signalling receptor binding, viral protein interaction, cell migration, external stimuli response, serine hydrolase activity and PI3K-Akt signalling pathway. Protein-protein interaction network analyses revealed the genes to be highly interconnected, whereas module analyses revealed 25 genes to possess the highest interaction score. Overall survival analyses delineated six genes (ADAMTSL4, SEMA5B, ADAMTS15, THBS2, SPON1 and THBS1) that can serve as biomarkers for prognosis for BL management.
Collapse
Affiliation(s)
- Albert Doughan
- Department of Biochemistry and BiotechnologyCollege of ScienceFaculty of BiosciencesKwame Nkrumah University of Science and Technology (KNUST)KumasiGhana
| | - Samson Pandam Salifu
- Department of Biochemistry and BiotechnologyCollege of ScienceFaculty of BiosciencesKwame Nkrumah University of Science and Technology (KNUST)KumasiGhana
- Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)KumasiGhana
| |
Collapse
|
2
|
Belpaire M, Taminiau A, Geerts D, Rezsohazy R. HOXA1, a breast cancer oncogene. Biochim Biophys Acta Rev Cancer 2022; 1877:188747. [PMID: 35675857 DOI: 10.1016/j.bbcan.2022.188747] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/27/2022] [Accepted: 06/01/2022] [Indexed: 12/24/2022]
Abstract
More than 25 years ago, the first literature records mentioned HOXA1 expression in human breast cancer. A few years later, HOXA1 was confirmed as a proper oncogene in mammary tissue. In the following two decades, molecular data about the mode of action of the HOXA1 protein, the factors contributing to activate and maintain HOXA1 gene expression and the identity of its target genes have accumulated and provide a wider view on the association of this transcription factor to breast oncogenesis. Large-scale transcriptomic data gathered from wide cohorts of patients further allowed refining the relationship between breast cancer type and HOXA1 expression. Several recent reports have reviewed the connection between cancer hallmarks and the biology of HOX genes in general. Here we take HOXA1 as a paradigm and propose an extensive overview of the molecular data centered on this oncoprotein, from what its expression modulators, to the interactors contributing to its oncogenic activities, and to the pathways and genes it controls. The data converge to an intricate picture that answers questions on the multi-modality of its oncogene activities, point towards better understanding of breast cancer aetiology and thereby provides an appraisal for treatment opportunities.
Collapse
Affiliation(s)
- Magali Belpaire
- Animal Molecular and Cellular Biology Group (AMCB), Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Louvain-la-Neuve, Belgium
| | - Arnaud Taminiau
- Animal Molecular and Cellular Biology Group (AMCB), Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Louvain-la-Neuve, Belgium
| | - Dirk Geerts
- Heart Failure Research Center, Amsterdam University Medical Center (AMC), Universiteit van Amsterdam, Amsterdam, the Netherlands.
| | - René Rezsohazy
- Animal Molecular and Cellular Biology Group (AMCB), Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Louvain-la-Neuve, Belgium.
| |
Collapse
|
3
|
Deng J, Liang L, Yi H, Su T, Yang Z, Nie L, Liu J. USP7 inhibition inhibits proliferation and induces megakaryocytic differentiation in MDS cells by upregulating gelsolin. Br J Haematol 2020; 190:418-429. [PMID: 32130729 DOI: 10.1111/bjh.16549] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 01/31/2020] [Indexed: 01/02/2023]
Abstract
Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is driven by complex genetic and epigenetic alterations from an aberrant clone of hematopoietic stem/progenitor cells (HSPCs). Ubiquitin-specific protease 7 (USP7) has been demonstrated to have an important oncogenic role in the development of several cancer types, but its role in MDS is unknown. Here, we demonstrate that USP7 expression is elevated in MDS cell lines and patient samples. The USP7-selective small-molecule inhibitors P5091 and P22077 inhibited cell proliferation and induced megakaryocytic differentiation in both cell lines and primary cells. Furthermore, pharmacological inhibition of USP7 markedly suppressed the growth of MDS cell lines in xenograft mouse models. To explore the mechanisms underlying the observed phenotypic changes, we employed RNA-seq to compare the differences in genes after USP7 inhibitor treatment and found that gelsolin (GSN) expression was increased significantly after USP7 inhibitor treatment. Furthermore, knockdown of GSN attenuated the proliferation inhibition, apoptosis induction and megakaryocyte differentiation induced by USP7 inhibitors in MDS cells. Collectively, our findings identify previously unknown roles of USP7 and suggest that the USP7/GSN axis may be a potential therapeutic target in MDS.
Collapse
Affiliation(s)
- Jinghui Deng
- Hematology Department, Hunan Province Key Laboratory of Basic and Applied Hematology, Xiangya Hospital, Central South University.,Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University
| | - Long Liang
- Hematology Department, Hunan Province Key Laboratory of Basic and Applied Hematology, Xiangya Hospital, Central South University.,Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University
| | - Hui Yi
- Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University
| | - Tao Su
- Hematology Department, Hunan Province Key Laboratory of Basic and Applied Hematology, Xiangya Hospital, Central South University
| | - Zhou Yang
- The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Ling Nie
- Hematology Department, Hunan Province Key Laboratory of Basic and Applied Hematology, Xiangya Hospital, Central South University
| | - Jing Liu
- Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University
| |
Collapse
|
4
|
Seccia V, Navari E, Donadio E, Boldrini C, Ciregia F, Ronci M, Aceto A, Dallan I, Lucacchini A, Casani AP, Mazzoni MR, Giusti L. Proteomic Investigation of Malignant Major Salivary Gland Tumors. Head Neck Pathol 2019; 14:362-373. [PMID: 31098787 PMCID: PMC7235111 DOI: 10.1007/s12105-019-01040-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 05/07/2019] [Indexed: 12/25/2022]
Abstract
The purpose of this study was to define the proteome profile of fine needle aspiration (FNA) samples of malignant major salivary gland tumors (MSGT) compared to benign counterparts, and to evaluate potential clinical correlations and future applications. Patients affected by MSGT (n = 20), pleomorphic adenoma (PA) (n = 37) and Warthin's tumor (WT) (n = 14) were enrolled. Demographic, clinical and histopathological data were registered for all patients. FNA samples were processed to obtain the protein extracts. Protein separation was obtained by two-dimensional electrophoresis (2-DE) and proteins were identified by mass spectrometry. Western blot analysis was performed to validate the 2-DE results. Statistical differences between groups were calculated by the Mann-Whitney U test for non-normal data. Spearman's rank correlation coefficient was calculated to evaluate correlations among suggested protein biomarkers and clinical parameters. Twelve and 27 differentially expressed spots were found for MSGT versus PA and MSGT versus WT, respectively. Among these, annexin-5, cofilin-1, peptidyl-prolyl-cis-trans-isomerase-A and F-actin-capping-alpha-1 were able to differentiate MSGT from PA, WT, and healthy samples. Moreover, STRING analysis suggested cofilin-1 as a key node of protein interactions. Some of the overexpressed proteins are related to some clinical factors of our cohort, such as survival and outcome. Our results suggest potential protein biomarkers of MSGT, which could allow for more appropriate treatment plans, as well as shedding light on the molecular pathways involved.
Collapse
Affiliation(s)
- Veronica Seccia
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, ENT Section, University of Pisa, Pisa, Italy
| | - Elena Navari
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, ENT Section, University of Pisa, Pisa, Italy
| | - Elena Donadio
- Department of Pharmacy, University of Pisa, Pisa, Italy
| | | | - Federica Ciregia
- Department of Rheumatology, GIGA Research, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Liège, Belgium
| | - Maurizio Ronci
- Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy
| | - Antonio Aceto
- Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy
| | - Iacopo Dallan
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, ENT Section, University of Pisa, Pisa, Italy
| | - Antonio Lucacchini
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Augusto Pietro Casani
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, ENT Section, University of Pisa, Pisa, Italy
| | | | - Laura Giusti
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy ,School of Pharmacy, University of Camerino, Via Gentile III da Varano, 62032 Camerino, Italy
| |
Collapse
|